Mechanisms of lower extremity vein dysfunction in chronic venous disease and implications in management of varicose veins

Abstract

Chronic venous disease (CVD) is a common venous disorder of the lower extremities. CVD can be manifested as varicose veins (VVs), with dilated and tortuous veins, dysfunctional valves and venous reflux. If not adequately treated, VVs could progress to chronic venous insufficiency (CVI) and lead to venous leg ulcer (VLU). Predisposing familial and genetic factors have been implicated in CVD. Additional environmental, behavioral and dietary factors including sedentary lifestyle and obesity may also contribute to CVD. Alterations in the mRNA expression, protein levels and proteolytic activity of matrix metalloproteinases (MMPs) have been detected in VVs and VLU. MMP expression/activity can be modulated by venous hydrostatic pressure, hypoxia, tissue metabolites, and inflammation. MMPs in turn increase proteolysis of different protein substrates in the extracellular matrix particularly collagen and elastin, leading to weakening of the vein wall. MMPs could also promote venous dilation by increasing the release of endothelium-derived vasodilators and activating potassium channels, leading to smooth muscle hyperpolarization and relaxation. Depending on VVs severity, management usually includes compression stockings, sclerotherapy and surgical removal. Venotonics have also been promoted to decrease the progression of VVs. Sulodexide has also shown benefits in VLU and CVI, and recent data suggest that it could improve venous smooth muscle contraction. Other lines of treatment including induction of endogenous tissue inhibitors of metalloproteinases and administration of exogenous synthetic inhibitors of MMPs are being explored, and could provide alternative strategies in the treatment of CVD.

Keywords

Extracellular matrix / matrix metalloproteinases / remodeling / varicose veins / vascular smooth muscle

References

[1] MacColl E.Matrix metalloproteinases as regulators of vein structure and function: implications in chronic venous disease.J Pharmacol Exp Ther2015;355:410-28 PMCID:PMC4658486

[2] Sansilvestri-Morel P,Rupin A.Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes?.Clin Sci (Lond)2007;112:229-39

[3] Cui N,Khalil RA.Biochemical and biological attributes of matrix metalloproteinases.Prog Mol Biol Transl Sci2017;147:1-73 PMCID:PMC5430303

[4] Kucukguven A.Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.Curr Drug Targets2013;14:287-324 PMCID:PMC3584231

[5] Chen Y,Raffetto JD.Matrix metalloproteinases in remodeling of lower extremity veins and chronic venous disease.Prog Mol Biol Transl Sci2017;147:267-99 PMCID:PMC5411014

[6] Raffetto JD,Mattana P.Sulodexide promotes venous contraction in rat inferior vena cava.J Vasc Surg Venous Lymphat Disord2017;5:145

[7] Raffetto JD,Wang X,Mattana P.Sulodexide improves contraction and decreases matrix metalloproteinase-2 and -9 in veins under prolonged stretch.J Cardiovasc Pharmacol2020;75:211-21 PMCID:PMC7060112

[8] Eklof B,Bergan JJ.Revision of the CEAP classification for chronic venous disorders: consensus statement.J Vasc Surg2004;40:1248-52

[9] Lurie F,Meisner M.The 2020 update of the CEAP classification system and reporting standards.J Vasc Surg Venous Lymphat Disord2020;8:342-52

[10] Beebe-Dimmer JL,Engle JS.The epidemiology of chronic venous insufficiency and varicose veins.Ann Epidemiol2005;15:175-84

[11] Raffetto JD.Mechanisms of varicose vein formation: valve dysfunction and wall dilation.Phlebology2008;23:85-98

[12] Zsoter T.Venous distensibility in patients with varicose veins.Can Med Assoc J1966;94:1293-7 PMCID:PMC1936709

[13] Naoum JJ,Woodside KJ.Current advances in the pathogenesis of varicose veins.J Surg Res2007;141:311-6

[14] Mannello F,Ligi D.Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases.Curr Vasc Pharmacol2013;11:354-65

[15] Naik B,Khanna AK.Clinico-histopathological study of varicose vein and role of matrix metalloproteinases-1, matrix metalloproteinases-9 and tissue inhibitor of matrix metalloproteinase-1 in varicose vein formation.Indian J Pathol Microbiol2016;59:25-30

[16] Gandhi RH,Nackman GB,Mulcare RJ.Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins.J Vasc Surg1993;18:814-20

[17] Haviarova Z,Stvrtinova V.The determination of the collagen and elastin amount in the human varicose vein by the computer morphometric method.Gen Physiol Biophys1999;18 Suppl 1:30-3

[18] Kockx MM,Bortier HE,Boutherin-Falson O.Vascular remodeling in varicose veins.Angiology1998;49:871-7

[19] Sansilvestri-Morel P,Jullien ND.Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3.J Vasc Res2005;42:388-98

[20] Venturi M,Annoni F.Biochemical assay of collagen and elastin in the normal and varicose vein wall.J Surg Res1996;60:245-8

[21] Corcos L,Dini M,Ferrari PA.Proximal long saphenous vein valves in primary venous insufficiency.J Mal Vasc2000;25:27-36

[22] Psaila JV.Viscoelastic properties and collagen content of the long saphenous vein in normal and varicose veins.Br J Surg1989;76:37-40

[23] Ono T,Schmid-Schonbein GW.Monocyte infiltration into venous valves.J Vasc Surg1998;27:158-66

[24] Raffetto JD,Beauregard KG.Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins.J Vasc Surg2010;51:972-81 PMCID:PMC2847594

[25] Mekky S,Walford J.Varicose veins in women cotton workers. An epidemiological study in England and Egypt.Br Med J1969;2:591-5 PMCID:PMC1983630

[26] Seidell JC,Deurenberg P,Hautvast JG.Overweight and chronic illness--a retrospective cohort study, with a follow-up of 6-17 years, in men and women of initially 20-50 years of age.J Chronic Dis1986;39:585-93

[27] Kaye SA,Soler JT,Potter JD.Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women.Int J Epidemiol1991;20:151-6

[28] Challis JRG,Gibb W.Endocrine and paracrine regulation of birth at term and preterm.Endocr Rev2000;21:514-50

[29] Bernstein IM,Badger GJ.Plasma volume expansion in early pregnancy.Obstet Gynecol2001;97:669-72

[30] Chapman AB,Zamudio S.Temporal relationships between hormonal and hemodynamic changes in early human pregnancy.Kidney Int1998;54:2056-63

[31] Stansby G.Women, pregnancy, and varicose veins.Lancet2000;355:1117-8

[32] Jawien A.The influence of environmental factors in chronic venous insufficiency.Angiology2003;54 Suppl 1:S19-31

[33] Lacroix P,Preux PM,Laskar M.Epidemiology of venous insufficiency in an occupational population.Int Angiol2003;22:172-6

[34] Abramson JH,Epstein LM.The epidemiology of varicose veins. A survey in western Jerusalem.J Epidemiol Community Health1981;35:213-7 PMCID:PMC1052160

[35] Lee S,Choe Y.Gene expression profiles in varicose veins using complementary DNA microarray.Dermatol Surg2005;31:391-5

[36] Anwar MA,Shalhoub J,Gohel MS.A review of familial, genetic, and congenital aspects of primary varicose vein disease.Circ Cardiovasc Genet2012;5:460-6

[37] Reagan B.Lower limb venous dynamics in normal persons and children of patients with varicose veins.Surg Gynecol Obstet1971;132:15-8

[38] Fukaya E,Lindholm D.Clinical and genetic determinants of varicose veins.Circulation2018;138:2869-80 PMCID:PMC6400474

[39] Badauy CM,Sant'Ana Filho M.Ehlers-Danlos syndrome (EDS) type IV: review of the literature.Clin Oral Investig2007;11:183-7

[40] Dalal A.Hemihyperplasia with Ehlers-Danlos syndrome like skin changes.Clin Dysmorphol2005;14:207-8

[41] McKusick VA.The defect in Marfan syndrome.Nature1991;352:279-81

[42] Ng MY,Spector TD.Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs.J Med Genet2005;42:235-9 PMCID:PMC1736007

[43] Serra R,de Franciscis A.A genetic study of chronic venous insufficiency.Ann Vasc Surg2012;26:636-42

[44] Noel AA,Cherry KJ Jr,Stanson AW.Surgical treatment of venous malformations in Klippel-Trenaunay syndrome.J Vasc Surg2000;32:840-7

[45] Delis KT,Wennberg PW,Driscoll DJ.Hemodynamic impairment, venous segmental disease, and clinical severity scoring in limbs with Klippel-Trenaunay syndrome.J Vasc Surg2007;45:561-7

[46] Saiki S,Saiki M.Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene.Neurology2006;67:337-9

[47] Xu HM,Zhang XM,Fu WG.Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins.J Surg Res2011;168:e143-8

[48] Xiao Y,Yin H,Wang S.Desmuslin gene knockdown causes altered expression of phenotype markers and differentiation of saphenous vein smooth muscle cells.J Vasc Surg2010;52:684-90

[49] Christopoulos D,Szendro G.Venous reflux: quantification and correlation with the clinical severity of chronic venous disease.Br J Surg1988;75:352-6

[50] Zamboni P,Lanzara V.Serum iron and matrix metalloproteinase-9 variations in limbs affected by chronic venous disease and venous leg ulcers.Dermatol Surg2005;31:644-9; discussion 649

[51] Zamboni P,Tognazzo S.The overlapping of local iron overload and HFE mutation in venous leg ulcer pathogenesis.Free Radic Biol Med2006;40:1869-73

[52] Zamboni P,Ongaro A.Factor XIII contrasts the effects of metalloproteinases in human dermal fibroblast cultured cells.Vasc Endovascular Surg2004;38:431-8

[53] Zamboni P,Izzo M.Hemochromatosis C282Y gene mutation increases the risk of venous leg ulceration.J Vasc Surg2005;42:309-14

[54] Tognazzo S,Palazzo A.Prognostic role of factor XIII gene variants in nonhealing venous leg ulcers.J Vasc Surg2006;44:815-9

[55] Gemmati D,Catozzi L.Influence of gene polymorphisms in ulcer healing process after superficial venous surgery.J Vasc Surg2006;44:554-62

[56] Dzieciuchowicz L,Paramo JA.Increased levels of metalloproteinase 10 and hemostatic markers in patients with noncomplicated primary varicose veins.Clin Appl Thromb Hemost2015;21:684-7

[57] Gillespie DL,Fileta B.Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13.J Surg Res2002;106:233-8

[58] Woodside KJ,Burke A.Morphologic characteristics of varicose veins: possible role of metalloproteinases.J Vasc Surg2003;38:162-9

[59] Thulesius O.The venous wall and valvular function in chronic venous insufficiency.Int Angiol1996;15:114-8

[60] Gomez I,Louedec L.Decreased PGE(2) content reduces MMP-1 activity and consequently increases collagen density in human varicose vein.PLoS One2014;9:e88021 PMCID:PMC3914898

[61] Serra R,Butrico L.From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases.Int Wound J2017;14:233-40

[62] Amato B,Compagna R.Role of matrix metalloproteinases in non-healing venous ulcers.Int Wound J2015;12:641-5

[63] Serra R,Buffone G.Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines.Int Wound J2016;13:53-8

[64] Asanuma K,Johnson C,Galis ZS.Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells.Am J Physiol Heart Circ Physiol2003;284:H1778-84

[65] Raffetto JD,Koledova VV.Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: Potential implications in varicose veins.J Vasc Surg2008;48:447-56 PMCID:PMC2575039

[66] Lim CS,Reslan OM.Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava.J Vasc Surg2011;53:764-73 PMCID:PMC3058747

[67] Milkiewicz M,Fudalewski T,Aghasi M.HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle.J Physiol2007;583:753-66 PMCID:PMC2277012

[68] Kim CH,Chun YS,Kim MS.Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway.Circ Res2002;90:E25-33

[69] Thodeti CK,Ravi A.TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling.Circ Res2009;104:1123-30 PMCID:PMC2754067

[70] Lim CS,Paleolog EM.Increased activation of the hypoxia-inducible factor pathway in varicose veins.J Vasc Surg2012;55:1427-39

[71] Misra S,Rajan DK.Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas.J Vasc Interv Radiol2008;19:252-9

[72] Anwar MA,Vorkas PA.In-vitro identification of distinctive metabolic signatures of intact varicose vein tissue via magic angle spinning nuclear magnetic resonance spectroscopy.Eur J Vasc Endovasc Surg2012;44:442-50

[73] Anwar MA,Li J.Prolonged mechanical circumferential stretch induces metabolic changes in rat inferior vena cava.Eur J Vasc Endovasc Surg2016;52:544-52 PMCID:PMC5056838

[74] Schmid-Schonbein GW,Bergan JJ.New advances in the understanding of the pathophysiology of chronic venous insufficiency.Angiology2001;52 Suppl 1:S27-34

[75] Mannello F.Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research.Am J Transl Res2011;3:149-58 PMCID:PMC3056561

[76] Raffetto JD,Maniscalco R,Mannello F.Why venous leg ulcers have difficulty healing: overview on pathophysiology, clinical consequences, and treatment.J Clin Med2020;10:29 PMCID:PMC7795034

[77] Zeng Y.Endothelial glycocalyx as a critical signalling platform integrating the extracellular haemodynamic forces and chemical signalling.J Cell Mol Med2017;21:1457-62 PMCID:PMC5542909

[78] Liu JX,Zhang YY,Liu XH.Hemodynamic shear stress regulates the transcriptional expression of heparan sulfate proteoglycans in human umbilical vein endothelial cell.Cell Mol Biol (Noisy-le-grand)2016;62:28-34

[79] Moazzam F,Zweifach BW.The leukocyte response to fluid stress.Proc Natl Acad Sci U S A1997;94:5338-43 PMCID:PMC24679

[80] Alsaigh T,Bergan JJ.Acute venous occlusion enhances matrix metalloprotease activity: Implications on endothelial dysfunction.Microvasc Res2011;81:108-16 PMCID:PMC3021174

[81] Takase S,Bergan JJ.Hypertension-induced venous valve remodeling.J Vasc Surg2004;39:1329-34

[82] Saito S,You R.Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency.J Vasc Surg2001;34:930-8

[83] Sayer GL.Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins.Eur J Vasc Endovasc Surg2004;28:479-83

[84] Aunapuu M.Histopathological changes and expression of adhesion molecules and laminin in varicose veins.Vasa2005;34:170-5

[85] Jacob MP,Scemama A.Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins.Circulation2002;106:535-8

[86] Sato H,Seiki M.v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.J Biol Chem1993;268:23460-8

[87] Reddy VS,Mummidi S.Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation.Am J Physiol Heart Circ Physiol2010;299:H1242-54 PMCID:PMC2957343

[88] Arbiser JL,Klafter R.Reactive oxygen generated by Nox1 triggers the angiogenic switch.Proc Natl Acad Sci U S A2002;99:715-20 PMCID:PMC117371

[89] Zubkova ES,Plekhanova OS,Ratner EI.Urokinase stimulates production of matrix metalloproteinase-9 in fibroblasts with involvement of reactive oxygen species.Bull Exp Biol Med2014;157:18-21

[90] Fu X,Bergt C.Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation.J Biol Chem2004;279:6209-12

[91] Bodnar E,Kovacs K.Redox Profiling Reveals Clear Differences between molecular patterns of wound fluids from acute and chronic wounds.Oxid Med Cell Longev2018;2018:5286785 PMCID:PMC6276414

[92] Foda HD,Drews M.Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340).Am J Respir Cell Mol Biol2001;25:717-24

[93] Norgauer J,Idzko M.Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers.Br J Dermatol2002;147:1180-6

[94] Majed BH.Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn.Pharmacol Rev2012;64:540-82 PMCID:PMC3400831

[95] Lee J,Subbarao T,Arosh JA.Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases.Mol Cell Endocrinol2011;332:306-13

[96] Takai S,Chen H.Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats.J Hypertens2014;32:1637-49

[97] Yin Z,Reslan OM,Khalil RA.Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones.Am J Physiol Endocrinol Metab2012;303:E55-70 PMCID:PMC3404560

[98] Dang Y,Tran V.EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone.Biochem Pharmacol2013;86:734-47 PMCID:PMC3812432

[99] Serra R,Conti A.The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs.Drug Des Devel Ther2014;8:519-27 PMCID:PMC4026398

[100] Badier-Commander C,Lebard C,Jacob MP.Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation.J Pathol2000;192:105-12

[101] Kirsch D,Kuchle R.Changes in the extracellular matrix of the vein wall--the cause of primary varicosis?.Vasa2000;29:173-7

[102] Sansilvestri-Morel P,Badier-Commander C.Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins.J Vasc Res2001;38:560-8

[103] Shi ZD,Berardi DE,Tarbell JM.Interstitial flow induces MMP-1 expression and vascular SMC migration in collagen I gels via an ERK1/2-dependent and c-Jun-mediated mechanism.Am J Physiol Heart Circ Physiol2010;298:H127-35 PMCID:PMC2806139

[104] Jin UH,Chang HW.Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway.J Cell Biochem2008;104:15-26

[105] Haque NS,Pan JJ,Harpel PC.Chemokine receptor-8 (CCR8) mediates human vascular smooth muscle cell chemotaxis and metalloproteinase-2 secretion.Blood2004;103:1296-304

[106] Cheng XW,Sasaki T.Increased expression of elastolytic cysteine proteases, cathepsins S and K, in the neointima of balloon-injured rat carotid arteries.Am J Pathol2004;164:243-51 PMCID:PMC1602234

[107] Johnson C.Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization.Arterioscler Thromb Vasc Biol2004;24:54-60

[108] Cho A.Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury.Circ Res2002;91:845-51

[109] Galis ZS,Godin D.Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling.Circ Res2002;91:852-9

[110] Aguilera CM,Johnson JL.Relationship between type IV collagen degradation, metalloproteinase activity and smooth muscle cell migration and proliferation in cultured human saphenous vein.Cardiovasc Res2003;58:679-88

[111] Carragher NO.Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion.Trends Cell Biol2004;14:241-9

[112] Nelson WJ.Convergence of Wnt, beta-catenin, and cadherin pathways.Science2004;303:1483-7 PMCID:PMC3372896

[113] Savani RC,Yang B.Migration of bovine aortic smooth muscle cells after wounding injury. The role of hyaluronan and RHAMM.J Clin Invest1995;95:1158-68 PMCID:PMC441453

[114] Uglow EB,Sala-Newby GB.Dismantling of cadherin-mediated cell-cell contacts modulates smooth muscle cell proliferation.Circ Res2003;92:1314-21

[115] Boire A,Agarwal A,Sherifi S.PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells.Cell2005;120:303-13

[116] Somers P.The histopathology of varicose vein disease.Angiology2006;57:546-55

[117] Wali MA.Smooth muscle changes in varicose veins: an ultrastructural study.J Smooth Muscle Res2001;37:123-35

[118] Wali MA.Intimal changes in varicose veins: an ultrastructural study.J Smooth Muscle Res2002;38:63-74

[119] Elsharawy MA,Abdelmaguid EM.Role of saphenous vein wall in the pathogenesis of primary varicose veins.Interact Cardiovasc Thorac Surg2007;6:219-24

[120] Xiao Y,Yin H,Wang S.In vitro differences between smooth muscle cells derived from varicose veins and normal veins.J Vasc Surg2009;50:1149-54

[121] Morla AO.Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase.Biochem Biophys Res Commun2000;272:298-302

[122] Karsdal MA,Engsig MT.Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis.J Biol Chem2002;277:44061-7

[123] Mao D,Lu H.Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.Tumour Biol2014;35:8217-23

[124] Zhang H,Jackson LF,Faber JE.Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle.Circ Res2004;95:989-97

[125] Frisch SM.Anoikis mechanisms.Curr Opin Cell Biol2001;13:555-62

[126] Almeida EA,Han Q.Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal kinase.J Cell Biol2000;149:741-54 PMCID:PMC2174844

[127] Ilic D,Schlaepfer DD,Aizawa S.Extracellular matrix survival signals transduced by focal adhesion kinase suppress p53-mediated apoptosis.J Cell Biol1998;143:547-60 PMCID:PMC2132850

[128] Levkau B,Karsan A.Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic pathway in human endothelial cells.Cell Death Differ2002;9:1360-7

[129] Visse R.Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.Circ Res2003;92:827-39

[130] Somerville RP,Apte SS.Matrix metalloproteinases: old dogs with new tricks.Genome Biol2003;4:216 PMCID:PMC193609

[131] Mannello F,Falcieri E.Multiple roles of matrix metalloproteinases during apoptosis.Apoptosis2005;10:19-24

[132] Bond M,Bennett MR.Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity.J Biol Chem2000;275:41358-63

[133] Kwan JA,Wang W.Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro.FASEB J2004;18:690-2

[134] Nagareddy PR,Hao L.Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K and mitochondrial ATP synthesis.Cardiovasc Res2009;84:368-77

[135] Chew DK,Khalil RA.Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction.J Vasc Surg2004;40:1001-10

[136] Raffetto JD,Wells AK.MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides.J Surg Res2010;159:755-64 PMCID:PMC2844458

[137] Waitkus-Edwards KR,Wu X.Alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction.Circ Res2002;90:473-80

[138] Macfarlane SR,Kanke T,Plevin R.Proteinase-activated receptors.Pharmacol Rev2001;53:245-82

[139] Hamilton JR,Cocks TM.Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries.Circ Res1998;82:1306-11

[140] Raffetto JD,Khalil RA.Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+ channels: relevance to varicose vein formation.J Vasc Surg2007;45:373-80 PMCID:PMC1794684

[141] Goerge T,Schnaeker EM.Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1 promoting endothelial cell activation.Cancer Res2006;66:7766-74

[142] Tarin C,Calvo E,Zaragoza C.Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis.Arterioscler Thromb Vasc Biol2009;29:27-32

[143] Louboutin JP,Reyes BA,Strayer DS.HIV-1 gp120-induced injury to the blood-brain barrier: role of metalloproteinases 2 and 9 and relationship to oxidative stress.J Neuropathol Exp Neurol2010;69:801-16 PMCID:PMC4707960

[144] Thanabalasundaram G,Lischper M.Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinases mediated activation of vascular endothelial growth factor in vitro.Brain Res2010;1347:1-10

[145] Lischper M,Thanabalasundaram G,Galla HJ.Metalloproteinase mediated occludin cleavage in the cerebral microcapillary endothelium under pathological conditions.Brain Res2010;1326:114-27

[146] Feletou M.Endothelium-derived hyperpolarizing factor: where are we now?.Arterioscler Thromb Vasc Biol2006;26:1215-25

[147] McNamara CA,Gimple LW,Coughlin SR.Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor.J Clin Invest1993;91:94-8 PMCID:PMC330000

[148] Coughlin SR.Thrombin signalling and protease-activated receptors.Nature2000;407:258-64

[149] Garcia JG,Bahler C,Hart CM.Thrombin receptor activating peptides induce Ca2+ mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium.J Cell Physiol1993;156:541-9

[150] Lee HY,Won JY.Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases.Arterioscler Thromb Vasc Biol2008;28:302-8

[151] Lattimer CR,Kafeza M,Geroulakos G.Quantifying the degree graduated elastic compression stockings enhance venous emptying.Eur J Vasc Endovasc Surg2014;47:75-80

[152] Horner J,Fernandes E.Value of graduated compression stockings in deep venous insufficiency.Br Med J1980;280:820-1 PMCID:PMC1600971

[153] Lattimer CR,Kalodiki E,Geroulakos G.Compression stockings significantly improve hemodynamic performance in post-thrombotic syndrome irrespective of class or length.J Vasc Surg2013;58:158-65

[154] Krajnovic P.Effect of a benzopyrone preparation in venous diseases during pregnancy.Med Monatsschr1977;31:86-8

[155] Bergan JJ.Chronic venous insufficiency and the therapeutic effects of Daflon 500 mg.Angiology2005;56 Suppl 1:S21-4

[156] Frick RW.Three treatments for chronic venous insufficiency: escin, hydroxyethylrutoside, and Daflon.Angiology2000;51:197-205

[157] Sirtori CR.Aescin: pharmacology, pharmacokinetics and therapeutic profile.Pharmacol Res2001;44:183-93

[158] Devehat C, Khodabandehlou T, Vimeux M, Kempf C. Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg.Int J Microcirc Clin Exp1997;17 Suppl 1:27-33

[159] Smith PD. From skin disorders to venous leg ulcers: pathophysiology and efficacy of Daflon 500 mg in ulcer healing.Angiology2003;54 Suppl 1:S45-50

[160] Siebert U,Sroczynski G.Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies.Int Angiol2002;21:305-15

[161] Pittler MH.Horse chestnut seed extract for chronic venous insufficiency.Cochrane Database Syst Rev2006;11:CD003230

[162] Berti F,Longiave D.The mode of action of aescin and the release of prostaglandins.Prostaglandins1977;14:241-9

[163] Carrasco OF.Endothelium protectant and contractile effects of the antivaricose principle escin in rat aorta.Vascul Pharmacol2007;47:68-73

[164] Savineau JP.Diosmin-induced increase in sensitivity to Ca2+ of the smooth muscle contractile apparatus in the rat isolated femoral vein.Br J Pharmacol1994;111:978-80 PMCID:PMC1910116

[165] Heijs BG, Blange T, Jongsma HJ, De Beer EL. The length dependency of calcium activated contractions in the femoral artery smooth muscle studied with different methods of skinning.J Muscle Res Cell Motil2000;21:59-66

[166] Kobayashi S,Somlyo AV.Cytosolic heparin inhibits muscarinic and alpha-adrenergic Ca2+ release in smooth muscle. Physiological role of inositol 1,4,5-trisphosphate in pharmacomechanical coupling.J Biol Chem1989;264:17997-8004

[167] Boudet C.Comparative effect of tropolone and diosmin on venous COMT and sympathetic activity in rat.Arch Int Pharmacodyn Ther1986;283:312-20

[168] Araujo D,Osswald W.Diosmin therapy alters the in vitro metabolism of noradrenaline by the varicose human saphenous vein.Pharmacol Res1991;24:253-6

[169] Raffetto JD.Ca(2+)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins.J Vasc Surg2011;54:489-96 PMCID:PMC3140579

[170] Cesarone MR,Pellegrini L.Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency.Angiology2006;57:131-8

[171] Raffetto JD,Dean SM,Mannello F.Pharmacologic treatment to improve venous leg ulcer healing.J Vasc Surg Venous Lymphat Disord2016;4:371-4

[172] Mann MW.Sclerotherapy: it is back and better.Clin Plast Surg2011;38:475-87, vii

[173] King JT,Vasquez M.Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance.Eur J Vasc Endovasc Surg2015;50:784-93

[174] Proebstle TM,Kargl A.Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles.J Vasc Surg2002;35:729-36

[175] Merchant RF,Myers KA.Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux.Dermatol Surg2005;31:129-34

[176] Min RJ,Zimmet SE.Endovenous laser treatment of saphenous vein reflux: long-term results.J Vasc Interv Radiol2003;14:991-6

[177] Sarin S,Coleridge Smith PD.Stripping of the long saphenous vein in the treatment of primary varicose veins.Br J Surg1994;81:1455-8

[178] Aremu MA,Butcher W.Prospective randomized controlled trial: conventional versus powered phlebectomy.J Vasc Surg2004;39:88-94

[179] Bootun R,Davies AH.The advent of non-thermal, non-tumescent techniques for treatment of varicose veins.Phlebology2016;31:5-14

[180] Tekin AI,Memetoglu ME.Nonthermal, nontumescent endovenous treatment of varicose veins.Ann Vasc Surg2016;36:231-5

[181] Andreozzi GM,Davi G.Sulodexide for the prevention of recurrent venous thromboembolism: the sulodexide in secondary prevention of recurrent deep vein thrombosis (SURVET) study: a multicenter, randomized, double-blind, placebo-controlled trial.Circulation2015;132:1891-7 PMCID:PMC4643750

[182] Coccheri S.Development and use of sulodexide in vascular diseases: implications for treatment.Drug Des Devel Ther2014;8:49-65 PMCID:PMC3879015

[183] Lauver DA.Sulodexide: a renewed interest in this glycosaminoglycan.Cardiovasc Drug Rev2006;24:214-26

[184] Coccheri S,Agnelli G,Palazzini E.Randomised, double blind, multicentre, placebo controlled study of sulodexide in the treatment of venous leg ulcers.Thromb Haemost2002;87:947-52

[185] Scondotto G,Ferrari P.Treatment of venous leg ulcers with sulodexide.Angiology1999;50:883-9

[186] Coccheri S.Biological and clinical effects of sulodexide in arterial disorders and diseases.Int Angiol2014;33:263-74

[187] Andreozzi GM.Role of sulodexide in the treatment of CVD.Int Angiol2014;33:255-62

[188] Liu YN,Li T.Sulodexide protects renal tubular epithelial cells from oxidative stress-induced injury via upregulating klotho expression at an early stage of diabetic kidney disease.J Diabetes Res2017;2017:4989847 PMCID:PMC5591972

[189] Pletinck A,Steppan S.Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion.Nephrol Dial Transplant2012;27:548-56

[190] Ligi D,Croce L.Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: Inhibitory effect of glycosaminoglycan sulodexide.Biochim Biophys Acta Mol Basis Dis2018;1864:3559-67

[191] Ciszewicz M,Antoniewicz A,Breborowicz A.Sulodexide suppresses inflammation in human endothelial cells and prevents glucose cytotoxicity.Transl Res2009;153:118-23

[192] Harenberg J.Review of pharmacodynamics, pharmacokinetics, and therapeutic properties of sulodexide.Med Res Rev1998;18:1-20

[193] Suminska-Jasinska K,Ciszewicz M,Antoniewicz A.Sulodexide reduces senescence-related changes in human endothelial cells.Med Sci Monit2011;17:CR222-6 PMCID:PMC3539523

[194] Polubinska A,Baum E,Breborowicz A.Sulodexide modifies intravascular homeostasis what affects function of the endothelium.Adv Med Sci2013;58:304-10

[195] Engberink RH, Heerspink HJ, de Zeeuw D, Vogt L. Blood pressure-lowering effects of sulodexide depend on albuminuria severity: post hoc analysis of the sulodexide microalbuminuria and macroalbuminuria studies.Br J Clin Pharmacol2016;82:1351-7 PMCID:PMC5061782

[196] Urbanek T,Begier-Krasinska B,Breborowicz A.Sulodexide suppresses inflammation in patients with chronic venous insufficiency.Int Angiol2015;34:589-96

[197] Raffetto JD,Mattana P.Sulodexide promotes arterial relaxation via endothelium-dependent nitric oxide-mediated pathway.Biochem Pharmacol2019;166:347-56 PMCID:PMC6602837

[198] Engberink RH, Rorije NM, Lambers Heerspink HJ, De Zeeuw D, van den Born BJ, Vogt L. The blood pressure lowering potential of sulodexide--a systematic review and meta-analysis.Br J Clin Pharmacol2015;80:1245-53 PMCID:PMC4693497

[199] Bode W,Grams F.Insights into MMP-TIMP interactions.Ann N Y Acad Sci1999;878:73-91

[200] Nagase H,Murphy G.Structure and function of matrix metalloproteinases and TIMPs.Cardiovasc Res2006;69:562-73

[201] Baker AH,Murphy G.Metalloproteinase inhibitors: biological actions and therapeutic opportunities.J Cell Sci2002;115:3719-27

[202] Batra J,Soares AS,Radisky DC.Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure.J Biol Chem2012;287:15935-46 PMCID:PMC3346077

[203] Aravind B,Navin T.Inhibitory effect of TIMP influences the morphology of varicose veins.Eur J Vasc Endovasc Surg2010;40:754-65

[204] Badier-Commander C,Henin D,Michel JB.Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study.J Pathol2001;193:398-407

[205] Caimi G,Montana M.Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with venous leg ulcers.Clin Hemorheol Microcirc2015;60:309-16

[206] Li PC,Sheu MJ,Ma WF.Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: an in vitro and in vivo study.PLoS One2014;9:e96927 PMCID:PMC4019650

[207] Benjamin MM.Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.Exp Suppl2012;103:209-79 PMCID:PMC3367802

[208] Hu J,Sang QX.Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.Nat Rev Drug Discov2007;6:480-98

[209] Jacobsen JA,Miller MT.To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition.Biochim Biophys Acta2010;1803:72-94

[210] Scozzafava A.Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes.J Med Chem2000;43:3677-87

[211] Pochetti G,Campestre C.Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates.J Med Chem2006;49:923-31

[212] Wojtowicz-Praga SM,Hawkins MJ.Matrix metalloproteinase inhibitors.Invest New Drugs1997;15:61-75

[213] Skiles JW,Jeng AY.The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.Curr Med Chem2001;8:425-74

[214] Puerta DT,Cohen SM.New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.J Am Chem Soc2004;126:8388-9

[215] Bernardo MM,Li ZH,Mobashery S.Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.J Biol Chem2002;277:11201-7

[216] Johnson AR,Ortwine DF.Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects.J Biol Chem2007;282:27781-91

[217] Chetty C,Joseph P,Rao JS.Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice.Mol Cancer Ther2006;5:2289-99

[218] Dorecka M,Garczorz W,Romaniuk W.The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment epithelial cells.Acta Biochim Pol2014;61:265-70

[219] Luan Z,Newby AC.Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages.Arterioscler Thromb Vasc Biol2003;23:769-75

[220] Ichihara S,Nagata K.Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure.Cardiovasc Res2006;69:726-35

[221] Chen Q,Yang F,Xiao Q.Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling.Mediators Inflamm2013;2013:928315 PMCID:PMC3694547

[222] Serra R,Buffone G.Doxycycline speeds up healing of chronic venous ulcers.Int Wound J2015;12:179-84

[223] Renkiewicz R,Lesch C.Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats.Arthritis Rheum2003;48:1742-9

[224] Chiarelli N,Zoppi N,Colombi M.Transcriptome analysis of skin fibroblasts with dominant negative COL3A1 mutations provides molecular insights into the etiopathology of vascular Ehlers-Danlos syndrome.PLoS One2018;13:e0191220 PMCID:PMC5773204

[225] Greenberg BR.Erythropoiesis in familial erythrocytosis.N Engl J Med1977;296:1080-4

[226] Ang SO,Hirota K.Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.Nat Genet2002;32:614-21

[227] Gordeuk VR,Miasnikova GY.Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors.Blood2004;103:3924-32

[228] Banka S,Newman WG.Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3.Eur J Hum Genet2011;19:18-22 PMCID:PMC3039503

[229] Yin H,Wang J.Downregulation of desmuslin in primary vein incompetence.J Vasc Surg2006;43:372-8

[230] Urbanek T,Wiaderkiewicz R.Smooth muscle cell apoptosis in primary varicose veins.Eur J Vasc Endovasc Surg2004;28:600-11

[231] Le Flem L,Aubry ML.Thrombomodulin promoter mutations, venous thrombosis, and varicose veins.Arterioscler Thromb Vasc Biol2001;21:445-51

[232] Wang Q,Szafranski P.Identification and molecular characterization of de novo translocation t(8;14)(q22.3;q13) associated with a vascular and tissue overgrowth syndrome.Cytogenet Cell Genet2001;95:183-8 PMCID:PMC1579861

[233] Tian XL,You SA.Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome.Nature2004;427:640-5 PMCID:PMC1618873

[234] Fang J,Erickson RP.Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the hereditary lymphedema-distichiasis syndrome.Am J Hum Genet2000;67:1382-8 PMCID:PMC1287915

[235] Brice G,Bell R.Analysis of the phenotypic abnormalities in lymphoedema-distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24.J Med Genet2002;39:478-83 PMCID:PMC1735188

[236] Mellor RH,Stanton AW.Mutations in FOXC2 are strongly associated with primary valve failure in veins of the lower limb.Circulation2007;115:1912-20

[237] Scappaticci S,Cortinovis M.Cytogenetic studies in venous tissue from patients with varicose veins.Cancer Genet Cytogenet1994;75:26-30

[238] Sam RC,Hobbs SD.The prevalence of hyperhomocysteinemia, methylene tetrahydrofolate reductase C677T mutation, and vitamin B12 and folate deficiency in patients with chronic venous insufficiency.J Vasc Surg2003;38:904-8

[239] Sverdlova AM,Baranovskaya SS,Avitisjan AO.Prevalence of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with varicose veins of lower limbs.Mol Genet Metab1998;63:35-6

[240] Gemmati D,Catozzi L.DNA-array of gene variants in venous leg ulcers: detection of prognostic indicators.J Vasc Surg2009;50:1444-51

[241] Nagy N,Szabad G.Single nucleotide polymorphisms of the fibroblast growth factor receptor 2 gene in patients with chronic venous insufficiency with leg ulcer.J Invest Dermatol2005;124:1085-8

[242] Janssens D,Guillaume G,Louagie Y.Increase in circulating endothelial cells in patients with primary chronic venous insufficiency: protective effect of Ginkor Fort in a randomized double-blind, placebo-controlled clinical trial.J Cardiovasc Pharmacol1999;33:7-11

[243] Geroulakos G.Controlled studies of Daflon 500 mg in chronic venous insufficiency.Angiology1994;45:549-53

[244] Falanga V,Diaz C.Systemic treatment of venous leg ulcers with high doses of pentoxifylline: efficacy in a randomized, placebo-controlled trial.Wound Repair Regen1999;7:208-13

[245] Kalus U,Grigorov A,Peil H.Improvement of cutaneous microcirculation and oxygen supply in patients with chronic venous insufficiency by orally administered extract of red vine leaves AS 195: a randomised, double-blind, placebo-controlled, crossover study.Drugs R D2004;5:63-71

[246] Milio G,Cospite V,Novo S.Efficacy of the treatment with prostaglandin E-1 in venous ulcers of the lower limbs.J Vasc Surg2005;42:304-8

[247] Kahle B.Efficacy of sclerotherapy in varicose veins-- prospective, blinded, placebo-controlled study.Dermatol Surg2004;30:723-8; discussion 728